UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

~~SECTION 13~~Date ORof 15Report (DDate of earliest event reported) OF: ~~THE~~January 31, 2017

~~SECURITIES~~21st ~~EXCHANGE~~CENTURY ~~ACT~~ONCOLOGY ~~OF 1934~~HOLDINGS, INC.

Date of Report (Date of earliest event reported): January 23, 2017

21st CENTURY ONCOLOGY

HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)

(State or Other Jurisdiction of Incorporation)

333-170812		26-1747745
(Commission File Number)		(I.R.S. Employer Identification No.)

2270 Colonial Boulevard		33907
Fort Myers, Florida		(Zip Code)
(Address of Principal Executive Offices)

333-170812		26-1747745
(Commission File Number)		(I.R.S. Employer Identification No.)

2270 Colonial Boulevard Fort Myers, Florida		33907
(Address of Principal Executive Offices)		(Zip Code)

(239) 931-7254
(Registrant’s Telephone Number, including Area Code)

N/A (Former Name or Former Address, if Changed Since Last Report.)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 51.0201 ~~Departure~~Entry ofinto ~~Directors~~a orMaterial ~~Certain~~Definitive ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Agreement.

OnAs ~~January 23,~~previously ~~2017~~disclosed, ~~Dr.~~on December ~~Daniel~~6, ~~E. Dosoretz~~2016, a21st ~~member~~Century ofOncology ~~the~~Holdings, Inc. ~~Board~~(“we,” of“our,” ~~Directors~~“us” (or the “~~Board~~Company”), of 21st Century Oncology ~~Holdings~~, Inc. (~~the~~ “~~Company~~21C”), ~~notified the Board of his decision to resign as~~ a ~~director~~subsidiary of the Company, ~~effective~~and ~~immediately.~~certain ~~The~~of the Company’s ~~thanks~~other ~~him~~subsidiaries ~~for~~entered ~~his~~into ~~time~~a ~~and~~Forbearance ~~dedicated~~Agreement ~~service~~relating onto the ~~Board. Dr. Dosoretz~~Company’s ~~continues~~indenture toand ~~serve as~~ a ~~Senior~~Forbearance ~~Physician~~Agreement ~~for~~relating to the Company,’s ~~and~~credit agreement (collectively, the ~~Company~~“Forbearance ~~looks~~Agreements”), ~~forward~~with tocertain ~~working~~of ~~with~~21C’s ~~Dr. Dosoretz~~noteholders and ~~his~~lenders, ~~affiliates~~respectively. toThe ~~continue~~Forbearance toAgreements ~~provide~~were ~~quality~~subsequently ~~care~~amended toon ~~its~~December 15, ~~patients~~2016 and ~~grow~~on ~~its~~January ~~business~~15, ~~for its extensive physician network and stakeholders~~2017.

~~Forward-Looking~~Effective ~~Statements~~as of January 31, 2017, we entered into amendments to the Forbearance Agreements (collectively, the “Amendments”) to, among other things, provide that the noteholders and lenders party thereto will forbear, subject to important exceptions, until the earlier of March 10, 2017 and the occurrence of certain events (as described in the Forbearance Agreements) from exercising any rights and remedies under 21C’s indenture, notes or credit agreement, as applicable, on account of certain events of default.

~~This~~In ~~Current~~addition, ~~Report~~effective onas ~~Form 8-K~~of ~~contains~~January ~~forward-looking~~31, ~~statements~~2017, ~~within~~Medical ~~the~~Developers, ~~meaning~~LLC, ofan ~~Section 27A~~indirect ofwholly ~~the~~owned ~~Securities~~subsidiary ~~Act and Section 21E~~ of the ~~Exchange~~Company ~~Act.~~and ~~Forward-looking~~certain ~~statements are based on management’s current expectations or beliefs. Readers~~ of ~~this~~its ~~Current~~affiliates, ~~Report~~entered oninto ~~Form 8-K~~an ~~are~~amendment ~~cautioned not~~ to ~~place undue reliance on forward-looking statements contained herein, which speak only as of~~ the ~~date~~MDL ofCredit ~~this~~and ~~Current~~Guarantee ~~Report~~Agreement ~~on Form 8-K. The Company undertakes no obligation~~ to ~~publicly~~extend ~~update or revise~~ the ~~forward-looking~~maturity ~~statements contained herein to reflect changed events or circumstances after the~~ date offrom ~~this~~January 31, ~~Current~~2017 ~~Report~~to onMarch ~~Form 8-K~~10, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	21st CENTURY ONCOLOGY HOLDINGS, INC.
Date: January 26, 2017	By:	/s/ LeAnne M. Stewart
Date: February 2, 2017	By:	/s/ LeAnne M. Stewart
		Name: LeAnne M. Stewart
		Name:	LeAnne M. Stewart
		Title: Chief Financial Officer
		Title:	Chief Financial Officer

Filing Compare · 21st Century Oncology Holdings, Inc.